Shots:
- Kashiv BioSciences has reported that Health Canada has validated and accepted the MAA for ADL-018, a biosimilar version of Xolair (omalizumab)
- Omalizumab is approved for multiple allergic & inflammatory conditions, incl. mod. to sev. persistent asthma (≥6yrs.), CRSwNP (≥18yrs.), chronic spontaneous urticaria (≥12 yrs.), & IgE-mediated food allergy (>1yr.)
- Additionally, Alvotech & Kashiv BioSciences have partnered to commercializeADL-018 across the EEA, the UK, Switzerland, Australia, New Zealand, & Canada
Ref: Businesswire | Image: Kashiv Biosciences | Press Release
Related News: Amneal Pharmaceuticals to Acquire Kashiv Biosciences for ~$1.1B
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
